ArriVent BioPharma appoints Brent Rice as chief commercial officer

NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP) has appointed Brent S. Rice as Chief Commercial Officer, the company announced Monday.

Rice joins the clinical-stage biopharmaceutical company with over 25 years of commercial experience in the biotechnology and pharmaceutical sectors. He most recently served as Senior Vice President and global Chief Commercial Officer at Autolus Therapeutics Ltd., where he led the company’s transition from clinical development to a commercial organization.

"Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent.

The appointment comes as ArriVent prepares for the potential approval and commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC). The company is also developing a portfolio of antibody drug conjugates.

Prior to Autolus, Rice led Managed Markets at Juno Therapeutics and spent 18 years at Amgen in roles of increasing responsibility.

"ArriVent has built a robust and science-driven pipeline that targets challenging and underserved areas in oncology," Rice said in the press release statement.

ArriVent focuses on identifying, developing, and commercializing medicines for cancer patients with unmet medical needs.

In other recent news, Autolus Therapeutics Ltd reported a notable earnings performance for the second quarter of 2025. The company posted an earnings per share (EPS) of -$0.18, exceeding analysts’ expectations, which had projected an EPS of -$0.23. This earnings beat indicates a better-than-anticipated financial result for the period. Despite this positive development, concerns remain regarding Autolus’s high net loss and increased expenses, which have drawn attention from investors. These financial challenges appear to have overshadowed the earnings surprise in the minds of some market participants. As a result, the stock experienced a notable decline in pre-market trading. These recent developments reflect ongoing investor scrutiny of the company’s financial health and operational costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.